Agents repurposed anti-itch drugs to neutralize the Bundibugyo ebolavirus (muni.bio)

A recent hackathon, dubbed Ebolathon, resulted in the successful identification of small molecules that can inhibit the entry of the Bundibugyo ebolavirus (BDBV). The event showcased an 18.6% hit rate, with 140 novel compounds designed and synthesized in just 11 lab days, a timeframe significantly shorter than the usual 3-6 weeks for similar projects. Notably, repurposed anti-itch medications such as endoxifen and tamoxifen emerged as leading candidates, demonstrating over 99% neutralization of BDBV and offering a promising avenue for rapid therapeutic development in light of the ongoing Ebola outbreaks in regions like the Democratic Republic of the Congo and Nigeria. The significance of this hackathon lies in its innovative integration of AI-driven automated synthesis and laboratory workflows, facilitated by partnerships with platforms like onepot. This approach not only accelerates drug discovery but also emphasizes the need for functional validation in biological assays, positioning AI as a key player in tackling viral diseases. As the AI/ML community enhances its drug design capabilities, the focus may shift from merely generating compounds to ensuring their efficacy and safety in real-world applications, ultimately driving advancements in public health interventions against emerging infectious diseases.